MAG (Myelin-Associated Glycoprotein) is a critical component of the myelin sheath in the central and peripheral nervous systems. It plays essential roles in maintaining myelin integrity, axonal-glial interactions, and has been implicated in various neurological disorders including multiple sclerosis (MS), hereditary spastic paraplegia (HSP), Charcot-Marie-Tooth disease (CMT), and amyotrophic lateral sclerosis (ALS).
MAG is a member of the siglec (sialic acid-binding immunoglobulin-type lectin) family and functions as a lectin that binds to sialylated glycoconjugates. It mediates critical cell-cell adhesion between myelin-forming glia (oligodendrocytes and Schwann cells) and axons, making it essential for both CNS and PNS myelination.
| Property |
Value |
| Gene Symbol |
MAG |
| Full Name |
Myelin-Associated Glycoprotein |
| Chromosomal Location |
19q13.12 |
| NCBI Gene ID |
4099 |
| OMIM |
159460 |
| Ensembl ID |
ENSG00000141670 |
| UniProt |
P20916 |
| Protein Type |
Type I membrane protein, Siglec family |
| Associated Diseases |
Multiple Sclerosis, Hereditary Spastic Paraplegia, CMT disease, ALS |
¶ Gene Structure and Protein
The MAG gene is located on chromosome 19q13.12 and encodes a type I transmembrane protein. The gene structure consists of multiple exons encoding distinct protein domains:
- Extracellular domain: Contains immunoglobulin-like domains that mediate sialic acid binding
- Transmembrane domain: Single pass membrane spanning region
- Cytoplasmic domain: Contains motifs for intracellular signaling and protein interactions
MAG is a member of the siglec family with the following structural features:
- N-terminal signal peptide: Targets protein for secretion/membrane insertion
- Immunoglobulin-like domains: Three Ig-like domains in the extracellular region
- Sialic acid binding site: Lectin domain recognizing specific sialylated glycoconjugates
- Transmembrane helix: Single hydrophobic transmembrane region
- Cytoplasmic tail: Contains multiple phosphorylation sites and protein interaction motifs
graph TD
A[MAG Protein] --> B[Extracellular Domain]
A --> C[Transmembrane Domain]
A --> D[Cytoplasmic Tail]
B --> B1[Ig-like Domain 1]
B --> B2[Ig-like Domain 2]
B --> B3[Ig-like Domain 3]
D --> D1[Phosphorylation Sites]
D --> D2[Protein Interaction Motifs]
¶ Myelin Formation and Maintenance
MAG plays multiple critical roles in the nervous system:
- Myelin Formation: Essential for the formation and maintenance of the myelin sheath in both CNS and PNS
- Axon-Glial Interaction: Mediates adhesion between myelin-forming glia and axons
- Axonal Protection: Prevents axonal degeneration through direct trophic support
- Signal Transduction: Activates downstream signaling in both oligodendrocytes and neurons
- Myelin Stability: Maintains the structural integrity of the myelin sheath
One of the most studied functions of MAG is its role as a potent inhibitor of axonal regeneration in the CNS:
- Nogo receptor complex: MAG binds to the Nogo receptor (NgR1) alongside other myelin-associated inhibitors
- Growth cone collapse: MAG binding triggers growth cone collapse and halts axon extension
- RhoA activation: MAG signaling activates RhoA, leading to cytoskeletal changes
- cAMP regulation: MAG suppresses cAMP levels in neurons, inhibiting regeneration
MAG provides trophic support to oligodendrocytes:
- Anti-apoptotic signaling: MAG activates pro-survival pathways in oligodendrocytes
- Myelin maintenance: Continuous MAG expression is required for long-term myelin integrity
- Response to injury: MAG expression changes in demyelinating conditions
MAG is significantly involved in MS pathology:
- Autoimmune target: MAG is a target of the autoimmune response in some MS patients
- Antibody detection: Anti-MAG antibodies are detected in a subset of MS patients
- Demyelination: Demyelination leads to MAG loss from affected areas
- Remyelination failure: MAG dysfunction may contribute to failed remyelination
- Therapeutic implications: Understanding MAG may lead to remyelination therapies
MAG mutations cause a specific form of hereditary spastic paraplegia (SPG75):
- Autosomal recessive: MAG-related HSP follows autosomal recessive inheritance
- Phenotype: Spastic paraplegia with additional neurological features
- Age of onset: Typically childhood onset
- Clinical features: Lower limb spasticity, weakness, and sometimes neuropathy
MAG is implicated in certain forms of CMT disease:
- CMT1A association: Altered MAG expression in CMT1A patients
- Compensatory role: Increased MAG may have compensatory function in CMT pathology
- Demyelination: MAG loss contributes to demyelination in CMT
- Animal models: MAG deficiency in mouse models recapitulates CMT features
Emerging research links MAG to ALS:
- Expression alterations: MAG expression is altered in ALS motor cortex and spinal cord
- Axonal dysfunction: MAG changes may contribute to axonal dysfunction in ALS
- Myelin pathology: MAG loss in myelin may precede motor neuron death
- Therapeutic potential: MAG-modulating strategies may provide neuroprotection
A distinct clinical entity involves anti-MAG antibodies:
- Autoimmune neuropathy: IgM antibodies against MAG cause peripheral neuropathy
- Clinical features: Demyelinating neuropathy with sensory ataxia
- Treatment: Immunomodulatory therapies targeted at antibody reduction
- Prognosis: Variable response to treatment
MAG is expressed in both CNS and PNS:
- Oligodendrocytes: Primary source of MAG in the CNS
- Myelinated axons: MAG located in periaxonal myelin membranes
- White matter: Highest expression in corpus callosum, internal capsule
- Specific regions: Cerebral white matter, cerebellar white matter, spinal cord
- Schwann cells: PNS myelinating cells express MAG
- Myelin sheaths: MAG in PNS myelin
- Nerve fibers: Peripheral nerves with large diameter axons
| Developmental Stage |
Expression Level |
Location |
| Embryonic |
Low |
Precursor cells |
| Early postnatal |
High |
Active myelination |
| Adult |
Moderate |
Mature myelin |
| Aging |
Reduced |
White matter |
MAG interacts with multiple proteins to mediate its functions:
| Interactor |
Interaction Type |
Function |
| NgR1 (Nogo receptor) |
Binding |
Inhibition of axon regeneration |
| p75NTR |
Co-receptor |
Signal transduction |
| Lingo-1 |
Complex formation |
Inhibitory complex |
| Gangliosides |
Lipid binding |
Membrane localization |
| Sialic acid residues |
Carbohydrate binding |
Ligand recognition |
| Oligodendrocyte proteins |
Various |
Myelin maintenance |
MAG activates several intracellular signaling pathways:
- RhoA pathway: Leads to growth cone collapse
- cAMP pathway: Suppresses cAMP levels
- PI3K/Akt pathway: Regulates cell survival
- MAPK pathway: Controls gene expression
- JNK pathway: Mediates stress responses
graph LR
A[MAG Binding] --> B[NgR1/p75NTR Complex]
B --> C[RhoA Activation]
B --> D[cAMP Reduction]
C --> E[Growth Cone Collapse]
D --> F[Inhibited Regeneration]
E --> G[Axon Outgrowth Blocked]
F --> G
MAG is a key target for remyelination strategies:
- Promyelination factors: Understanding MAG regulation may identify therapeutic targets
- Antibody blockade: Blocking inhibitory MAG signaling may enhance remyelination
- Combination approaches: Targeting MAG with other myelin proteins
- Differentiation: Promoting oligodendrocyte differentiation
Inhibiting MAG may promote regeneration after CNS injury:
- NgR1 antagonists: Blocking the MAG-NgR1 interaction
- Anti-MAG antibodies: Neutralizing antibody fragments
- Small molecule inhibitors: Targeting MAG signaling pathways
- Gene therapy: Reducing MAG expression in injured neurons
MAG-based neuroprotective approaches are being explored:
- MAG mimetics: Designing MAG-blocking peptides
- Cell therapy: Transplanting cells engineered to modulate MAG
- Gene therapy: Delivering MAG modulators to the CNS
- Combination therapy: MAG targeting with other neuroprotective agents
- Precise signaling mechanisms: Complete pathway mapping
- Remyelination role: How MAG affects remyelination efficiency
- Therapeutic translation: Developing clinically relevant MAG modulators
- Biomarkers: MAG as disease progression marker
- Structural studies: MAG-sialic acid interaction at atomic resolution
- In vivo imaging: Developing MAG-specific imaging agents
- Clinical trials: Testing MAG-targeted therapies in human trials
- Precision medicine: Personalizing MAG-based treatments